← ANALYST RATINGS · TIPRANKS
ALX Oncology Holdings (ALXO): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $4.33, the highest $5.00, the lowest $4.00. The average is +308.8% from the last price of $1.06.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.85 → $0.96+12.4% | Hold | −9.4% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.85 → $0.96+13.1% | Hold | −9.4% | Upgrade | 16.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.86 → $0.95+11.3% | Hold | −9.9% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.85 → $0.89+4.8% | Sell | −16.0% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.84 → $0.95+13.6% | Sell | −10.4% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.84 → $0.94+11.9% | Sell | −11.3% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $4.00 | Buy | +277.4% | Reiterated | 01.10.26on TipRanks 10:20 | −6.7%next day −6.9% · 5 days −10.5% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $5.00 | Buy | +371.7% | Reiterated | 21.09.26on TipRanks 10:00 | −3.9%next day −3.6% · 5 days −15.2% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $4.00 | Buy | +277.4% | Reiterated | 17.08.26on TipRanks 07:38 | +1.0%next day +6.3% · 5 days +2.2% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | — | Hold | — | Reiterated | 06.08.26on TipRanks 20:45 | −1.1%next day −1.9% · 5 days −7.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $6.00 | Buy | +466.0% | Reiterated | 12.05.26on TipRanks 06:35 | −2.3%next day −0.6% · 5 days −2.8% | ↗ |
| Unknown Analyst | Jefferies | $4.00 | Buy | +277.4% | Initiated | 13.11.25on TipRanks 11:05 | −3.0%next day +13.1% · 5 days +14.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ALX Oncology Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $4.33 at a price of $1.39 (+211.8%); now: $4.33 at $1.06 (+308.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 4 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.16 to $-0.10). Last quarter: $-0.13.
Best top-analyst consensus in the sector · Healthcare
About ALX Oncology Holdings
- CEO: Jason Lettmann
- Employees: 48
- 323 Allerton Avenue, South San Francisco, CA, 94080, US
- www.alxoncology.com
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 84 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗